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Dementia is a common feature in Parkinson’s disease (PD) and is considered to be the result of limbic and cortical Lewy bodies
and/or Alzheimer changes. Astrogliosis may also aﬀect the development of dementia, since it correlates well with declining
cognition in Alzheimer patients. Thus, we determined whether cortical astrogliosis occurs in PD, whether it is related to dementia,
and whether this is reﬂected by the presence of glial ﬁbrillary acidic protein (GFAP) and vimentin in cerebrospinal ﬂuid (CSF).
We have examined these proteins by immunohistochemistry in the frontal cortex and by Western blot in CSF of cases with PD, PD
with dementia (PDD), dementia with Lewy bodies (DLB) and nondemented controls. We were neither able to detect an increase
in cortical astrogliosis in PD, PDD, or DLB nor could we observe a correlation between the extent of astrogliosis and the degree
of dementia. The levels of GFAP and vimentin in CSF did not correlate to the extent of astrogliosis or dementia. We did conﬁrm
the previously identiﬁed positive correlation between the presence of cortical Lewy bodies and dementia in PD. In conclusion, we
have shown that cortical astrogliosis is not associated with the cognitive decline in Lewy body-related dementia.
1.Introduction
Parkinson’s disease (PD) is a progressive neurological dis-
order characterized by motor symptoms such as tremor,
bradykinesia, rigidity, and postural instability. It is associated
with an almost complete degenerative loss of dopamine
neurons in the substantia nigra (SN) pars compacta and the
presence of Lewy bodies (LBs) and Lewy neurites (LNs).
The latter pathological hallmarks initially occur, according
to Braak and colleagues, in the glossopharyngeal and vagal
nerves and the anterior olfactory nucleus, and thereafter
spread to other brain nuclei and cortical areas [1]. This
topological progression of the disease, however, is currently
being critically evaluated in the ﬁeld [2–4]. In any case, a
majorcomponentoftheseLBsandLNsisanaggregatedform
of the presynaptic protein α-synuclein [1].
More recently, it has become apparent that cognitive
dysfunction is also an important clinical component of PD.
About two-third of the patients develop cognitive deﬁcits
within 3.5 years from the disease onset [5] ,a n du pt o
40% of idiopathic PD patients will develop dementia (PD
with dementia, PDD) based on population-based studies
(reviewed in [6]). The cognitive deﬁcits and dementia are
considered to be the result of the limbic and cortical LBs
[5], although the presence of Alzheimer changes, such as
neuroﬁbrillary tangles and amyloid depositions may also
play a role in some elderly PD patients. LBs are not
speciﬁc for PD and are also found in dementia with Lewy
bodies (DLBs). DLB is currently considered to be part of
a spectrum of dementias related to cortical LB disease,
instead of a speciﬁc disease entity, as neither the proﬁle
of cognitive deﬁcits nor the amount of LB pathology
allow diﬀerentiation between DLB and PDD (reviewed in
[7]). The dementia seen in PDD and DLB is typically a
deﬁcit in executive functions, resembling the symptoms seen
in frontal lobe patients (reviewed in [6]). A number of
neuropathological and neurochemical changes have been
linked to LB-related dementias, amongst which cholinergic2 Parkinson’s Disease
deﬁciency, Alzheimer’s disease (AD) pathology, and cortical
LBs. However, there is no association between the number of
cortical LBs and the timing of dementia, which suggests that
there may be other factors involved [7]. A factor that has not
beeninvestigatedwithregardtothedevelopmentofcognitive
changes is astrogliosis, which is an interesting candidate as
it has already been shown to be correlated to the cognitive
status in AD patients [8].
Astrocytes have many functions in the CNS (recently
reviewed by [9–11]), such as regulation of local vasodilation
and blood ﬂow, provision of energy metabolites to neurons,
participation in synaptic function and plasticity, modulation
of neuronal communication, and maintenance of the extra-
cellular balance of ions, ﬂuids, and transmitters. In response
to CNS injury or during the course of a neurodegenerative
disease, astrocytes become reactive, which is characterized
by hypertrophy of cellular processes and upregulation of
the intermediate ﬁlament proteins vimentin, GFAP, nestin,
and synemin [12]. Depending on the context of activation,
reactive astrocytes are involved in neuronal survival and
regeneration in either a protective or impedimental way
(reviewed in [13]). In AD, the extent of astrogliosis, as
shown by GFAP levels in both cortex and cerebrospinal
ﬂuid (CSF) is correlated to the degree of dementia [14, 15].
This suggests that the dementia might be partly due to
a pathological modiﬁcation in the function of astrocytes
instigated by reactive gliosis, leading to a change in their
synapse modulating activities.
Scientiﬁc literature on astrogliosis in PD is limited, and
contradicting data have been reported. In rodent models,
induced by toxins, reactive astrocytes are observed in the
ﬁrst days after model induction [17, 18]. In the 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine(MPTP)model,theastro-
cytic reaction in the SN and striatum follows microglia
activation and parallels the time course of dopaminergic
cell death in the SN. In these animals, the GFAP expression
remains upregulated, even after most dopaminergic neurons
have died due to MPTP intoxication [18]. In the 6-hydroxy
dopamine(6-OHDA)model,GFAPupregulationistransient
and returns to control levels after 28 days [17]. Furthermore,
6-OHDA injection in the SN or medial forebrain bundle can
induceGFAPchangesoverlongdistancesinthestriatumand
even in the cortex [17, 19]. In the human brain, inconsistent
results have been found; in two studies no evidence for
GFAP upregulation in the SN and putamen of PD patients
was found [20, 21], other studies, however, did show the
presence of reactive astrocytes, and thus an increase in
GFAP, in the SN [22–25]. In addition, astrocytes in the
parkinsonian brain upregulate DnaJB6, a protein that is also
found in LBs [26]. These contradicting studies and the lack
of information on astrogliosis in PD-related dementias led
us to question whether the frontal-type dementia in PD is
related to astrogliosis in the frontal lobe of PD brains. We
chose to study the frontal cortex both because the dementia
in PD presents with frontal deﬁcits [6], and because LB load
in the frontal cortex is an indicator of cognitive impairment
in PD patients [27]. We hypothesized that reactive astrocytes
in frontal cortical areas of PD brains are associated with the
occurrence of dementia, and that this is reﬂected in GFAP
and vimentin levels in the CSF. If this is true, the astrocytic
CSFmarkerscanbepotentiallyusedasadiagnosticindicator
for astrocyte dysfunction and dementia. In addition, we
investigated α-synuclein pathology in the frontal cortex to
determine its correlation to dementia in the PDD and DLB
cases studied.
2.MaterialsandMethods
2.1. Brain Tissue and Donor Selection. Human postmortem
tissue was obtained from the Netherlands Brain Bank (NBB;
Amsterdam, The Netherlands). The NBB performs rapid
brain autopsies, and the brain donors have given written
informed consent for using the tissue and for accessing
the extensive neuropathological and clinical information
for scientiﬁc research, in compliance with ethical and legal
guidelines[31].Allautopsiesareperformedatthedesignated
premises of the VU University medical center in Amsterdam.
Diagnosticexaminationanddissectionofthecentralnervous
system organs are performed by pathologists registered in
accordance with Individual Health Care Professions Act.
The independent Review Board of the VU University med-
ical center has reviewed and agreed with the procedures
of the Netherlands Brain Bank concerning “donation of
brain material for scientiﬁc research”. Two brain donors
in our cohort requested euthanasia as they suﬀered from
metastasized carcinoma (see Table 2). According to Dutch
law, euthanasia is legal. The drugs to induce euthanasia
in donor 2001-046 were a cocktail of fentanyl (an opiate
agonist), midazolam (a benzodiazepine), thiopental (rapid-
onset short-acting barbiturate general anaesthetic), and
pancuronium (a muscle relaxant). Donor 2004-045 passed
away after receiving thiopental and pancuronium. Extensive
neuropathological examinations show that the brains of
these cases were not metastasized by the tumour. One
patient had a small subependymoma, but this was clinically
irrelevant according to the neuropathologist. Furthermore,
GFAP and vimentin expression of these donors was not
markedly increased or decreased as compared to the other
donors. Therefore, it is unlikely that the drugs by which
euthanasia was induced aﬀected our data.
For this study, we selected 40 cases, divided into four
diagnostic groups (see details in Table 1) based on the
clinical and pathological data from the NBB. The ﬁrst
group consisted of 10 neurological control cases, for which
the clinical ﬁles did not report a history of neurological
diseases, cognitive problems or memory deﬁcits. In addition,
these cases did not show Lewy body pathology. The second
group included 9 cases diagnosed with PD without reported
memory problems or dementia. The third group included
11 cases diagnosed with PDD, and the last group consisted
of 10 cases diagnosed with DLB. The diagnosis PDD is
given to cases that present ﬁrst with PD and develop
dementia after at least a year, while DLB patients show
cognitive problems ﬁrst [7]. Groups were matched for sex,
age (P = 0.301), brain weight (P = 0.284), and postmortem
delay (PMD; P = 0.229) (see Table 1). Only cases with
an Alzheimer score [28] of Braak 0 or 1 were included,Parkinson’s Disease 3
Table 1: Clinicopathological data per group.
Diagnosis Sex (M/F) Age (yrs) PMD (hrs:
min)
Brain weight
(gr.)
Age of
onset (yrs)
Disease
duration
(yrs)
GDS PD Braak stage
Control 7/3 82 06:07 1350 — — n.d. 0 (n = 6)
PD 7/2 79 05:35 1289 64 15 n.d. 5.0 (n = 5)
PDD 7/4 76 05:50 1276 69 10 5 (n = 7) 6.0 (n = 8)
DLB 7/3 75 04:20 1211 66 7 7 (n = 10) 5.0 (n = 2)
Median values are given; Control: nondemented control; PD: Parkinson’s disease; PDD: PD with dementia; DLB: dementia with Lewy bodies; M: males; F:
females; PMD: postmortem delay; GDS: global deterioration scale [16]; n.d.: not determined. There is no signiﬁcant diﬀerence between the age (P = 0.301),
the brain weight (P = 0.284), and the postmortem delay (PMD; P = 0.229) of the groups. The mean GDS scores of the DLB group signiﬁcantly higher than
of the PDD group (P = 0.004). All other donor parameters, such as amyloid pathology and ApoE genotype (see also Tables 1 and 2), were not signiﬁcantly
diﬀerent between the groups.
assuring the absence of tangles in the frontal cortex and,
therefore, excluding these Alzheimer changes as the primary
cause of the dementia. The amyloid deposition was quite
variable, and scores between O (no amyloid deposition) and
C(extensiveamyloiddeposition)werepresentineachgroup.
A score for dementia (Reisberg scale/global deterioration
scale; GDS [16]) was available for 8 out of 11 PDD cases and
9 out of 10 DLB cases. A GDS score of 1 implies no cognitive
decline; a GDS score of 7 implies a very severe cognitive
decline, that is, dementia. No GDS scores were available of
the control and PD group, but the clinical history indicated
normal cognitive functioning. These cases were, therefore,
excluded from tests in which GDS scores were analyzed.
Comparing the mean GDS scores between the DLB group
and the PDD group showed a signiﬁcant diﬀerence between
the two groups (P = 0.004), with a higher median GDS
score (median = 7.00) in cases with LBD than cases with
PDD (median = 5.00). All other donor parameters, such as
amyloid pathology and ApoE genotype (see also Tables 1 and
2), were not signiﬁcantly diﬀerent between the groups.
PD case NBB 2002-105 had unusual high scores of both
GFAP levels in CSF (intensity = 119.8; median = 4.36) and
the number of vimentin-positive cells in cortical grey matter
(5676cells/mm3; median = 864.5). This donor died after a
stroke, which caused damage to the frontal lobe. Therefore,
we have excluded this case from further analysis.
From almost all of the 40 cases, both frontal lobe sections
and CSF were available for analysis. We obtained paraﬃn-
embedded orbitofrontal or medial frontal lobe sections
for 35 of the 40 cases (Table 2), which were used for
immunohistochemical analysis. Postmortem CSF samples,
obtained by the NBB at autopsy, were available for 37 of the
40 cases (Table 2)a n dw e r es t o r e da t−80◦C until Western
blot analysis.
2.2. Immunohistochemistry. 8μm-thick sections of formalin-
ﬁxed, paraﬃn-embedded frontal cortex were stained for
GFAP and vimentin as described before [32]. In brief,
the sections were steamed in Tris-buﬀered saline (TBS:
0.025M Tris, 0.14M NaCl, pH 7.6, and 98◦C), to provide
optimal antigen retrieval. Then, they were preincubated
in horse serum-containing buﬀer, and incubated overnight
in the primary antibody solution (GFAP 1:1000, DAKO
Z0334, DAKO A/S, Glostrup, Denmark; vimentin 1:5000,
Chemicon AB5733, Millipore, Billerica, MA, USA) for 16–24
hours. Subsequently, sections were incubated with biotiny-
lated secondary antibodies, avidin-biotin complex (ABC),
anddiaminobenzidinetetrahydrochloride(DAB)withnickel
sulfate (NiSO4; Sigma-Aldrich, St. Louis, MO, USA).
α-synuclein immunostaining was performed according
to the NBB standard protocol. Deparaﬃnized frontal cortex
sectionswerebroughttoaboilincitratebuﬀer(9.4mMcitric
acid, 40mM sodium citrate, and pH 6.0) and then boiled for
10 minutes. After cooling, they were washed twice in water
and incubated in 80% formic acid for 5 minutes. Then, they
were washed twice in water and once in phosphate buﬀered
saline (PBS; 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4,
2mMKH 2PO4, and pH 7.4), before incubation with anti-
α-synuclein antibody (1:500; NCL-L-ASYN, Novocastra,
Newcastle upon Tyne, UK) in PBS with 1% BSA. Sections
were incubated with this antibody for two hours at room
temperatureand16hoursat4◦Candthenwashedtwicewith
PBS. Immunoreactivity was visualized using the EnVision
+ Dual Link System-HRP (DAKO): sections were incubated
in Labeled Polymer-HRP for 1 hour, washed twice, and
then incubated for 10 minutes in liquid DAB+ substrate
(DAKO). Then, they were washed in water, dehydrated, and
embedded.
2.3. Image Acquisition and Analysis. Images of single im-
munostainings were obtained on an AxioSkop microscope
(Zeiss,Oberkochen,Germany)withNeoplanﬂuorobjectives,
usingaSonyXC77blackandwhitecamera(Sony,Japan)and
ImagePro software (MediaCybernetics, Bethesda, USA).
For quantiﬁcation of GFAP immunoreactivity, ﬁve
imagesweretaken,at20xmagniﬁcation,atrandomlocations
in grey and white matter separately. The pial layer was
excluded from analysis. In the images, the background
intensitywasmeasuredandathresholdof1.7timestheback-
ground was set to measure the immunopositive surface area.
Immunoreactive blood vessels and nonspeciﬁc staining were
edited out before quantiﬁcation. For each area the surface
percentage occupied with GFAP-positive immunostaining
was estimated by dividing the surface of the GFAP-positive
area by the total area analyzed. Additionally, for each section4 Parkinson’s Disease
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the ﬁve areas were averaged for both white and grey matter
regions.
For the vimentin analysis, no automated image analysis
couldbeconducted,duetothehighincidenceofbloodvessel
staining. Therefore, vimentin-positive cells were manually
identiﬁed in 15 randomly selected white and adjacent grey
matterareas,whichwerephotographedat20xmagniﬁcation.
Again, the pial layer was excluded from analysis. Vimentin-
positive astrocytes were identiﬁed based on their characteris-
tic morphology. Average vimentin-positive cell densities per
mm3 for both regions were calculated by dividing the cell
counts by the total volume measured. For quantiﬁcation of
α-synuclein pathology, whole sections were examined, and
thetotalnumberofLBswascounted.Inaddition, thesurface
area of the section was measured, which was used to correct
LB numbers for section volume.
2.4. Immunoblotting. CSF of the previously described 37
cases was obtained from the NBB. Samples were prepared by
mixing 10μLC S Fw i t h1 0μL 20x SDS loading buﬀer, con-
taining Bromophenol blue and 1μL of dithiothreitol (DTT;
2M ) .S a m p l e sw e r eh e a t e da t9 5 ◦Cf o r5m i n u t e sa n dl o a d e d
onto 7.5% polyacrylamide gels for Western blotting. The
proteins were transferred to a nitrocellulose membrane with
the use of a semidry blotter. After incubating in Supermix
(3.8mM Tris; 15mM NaCl; 60mM Gelatin; 0.5% Triton
X-100; pH 7.4) for 15 minutes, the nitrocellulose blot was
incubated with anti-GFAP (1:50.000, DAKO, recognizing
a l li s o f o r m so fG F A P[ 33]) and anti-vimentin (1:7000,
Chemicon) overnight at 4◦C. After rinsing three times in
TBS with 0.05% Tween 20 (TBS-T), the antibody/antigen
complexes were identiﬁed by incubating the blots with anti-
rabbit IRdye 800 (1:5000; Rockland) and anti-chicken Cy5
(1:2000) for 1 hour at room temperature. After washing in
TBS-T for 3 times, protein bands were analyzed for intensity
and corrected for background intensity with an Odyssey
Infrared Imaging System (LI-COR Biosciences, Lincoln,
USA).
2.5. Statistical Analysis. For statistical analysis, the program
SPSS Inc 17.0 was used. All tests performed were nonpara-
metric analyses, as most of our data was not normally dis-
tributed. We used the Mann-Whitney test for comparison of
two groups and the Kruskall-Wallis test for multiple groups.
Correlation analysis was performed using the Spearman test.
Statistical signiﬁcance was accepted when P ≤ 0.05.
3. Results
3.1. Astrogliosis Is Not Correlated with LB-Related Neuro-
pathology or Dementia. Astrocytes were abundant in both
grey and white matter of the frontal cortex. Morphology of
GFAP-positive astrocytes and the intensity of the staining
did not diﬀer much between grey (Figures 1(a)–1(d))a n d
white matter (Figures 1(e)–1(h); P = 0.778). The number
of vimentin-positive astrocytes was higher in white matter
(Figures 2(e)–2(h), median = 2533.0) than in grey matter
(Figures 2(a)–2(d), median = 853.7, P<0.0001). GFAP
expressioninfrontalgreymattercorrelatedwiththatinwhite
matter (r = 0.441; P = 0.009) as well as with vimentin cell
numbers in grey matter (r = 0.481; P = 0.005). Vimentin
cell numbers were also correlated in grey and white matter
(r = 0.465; P = 0.006). Furthermore, we observed a positive
correlation between the age of the donors and GFAP (r =
0.421; P = 0.013; Figure 1(k)) and vimentin (r = 0.470;
P = 0.006; Figure 2(k)) expression in grey matter.
When comparing the four diagnostic groups, GFAP
expression in both grey and white matter was not signif-
icantly diﬀerent in any of the groups (Figures 1(i)-1(j),
Table 3,P = 0.755 and P = 0.281). The number of vimentin-
positive cells was also unaltered in the PD, PDD and DLB
groups compared to controls (Figures 2(i)-2(j), Table 3, P =
0.590 and P = 0.503). In addition, we found no signiﬁcant
correlations between GFAP and vimentin expression and the
available clinical and neuropathological data, such as sex
(P = 0.956 for GFAP in grey matter, 0.086 for GFAP in
white matter, 0.802 for vimentin in grey matter, and 0.524
for vimentin in white matter), postmortem delay (PMD;
P = 0.165, 0.513, 0.878, and 0.473), amyloid deposition
(P = 0.111, 0.549, 0.300, and 0.389), GDS (P = 0.856, 0.382,
0.090, and 0.352), and ApoE genotype (P = 0.266, 0.942,
0.604, and 0.599).
3.2. GFAP and Vimentin Levels in CSF. GFAP was read-
ily detectable in postmortem CSF of all patient groups,
vimentin was found in some donors, unrelated to diagnosis
(Figure 3(a), Table 3). The protein levels were not diﬀerent
between the four diagnostic groups (Figures 3(c)-3(d), P =
0.055 for GFAP, P = 0.156 for vimentin) and did not
correlate to GDS scores (P = 0.513 and 0.519). There was
a signiﬁcant correlation between the intensity of the GFAP
and the vimentin signals on the Western blot (r = 0.413;
P = 0.012; Figure 3(b)). No signiﬁcant correlations between
Western blot values and frontal cortex levels of GFAP were
found (P = 0.4 7 4f o rg r e ym a t t e ra n dP = 0.542 for
white matter). For vimentin, CSF protein levels negatively
correlated with grey matter immunoreactivity (P = 0.046),
but not with white matter expression (P = 0.445). Therefore,
the levels of GFAP and vimentin do not reﬂect the state
of astrogliosis in the frontal cortex. Also, we did not ﬁnd
correlations between GFAP and vimentin protein levels and
the clinicopathological parameters, such as sex (P = 0.903
for GFAP and 0.135 for vimentin), PMD (P = 0.903 and
0.166), amyloid score (P = 0.397 and 0.399), and ApoE
genotype (P = 0.278 and 0.255).
3.3. Dementia in PD Is Correlated to Lewy Body Numbers in
the Frontal Cortex. Previous studies have suggested a role
of cortical LB pathology in PDD and DLB. Therefore, we
quantiﬁed the number of LBs (Figures 4(a)–4(d),a r r o w s )i n
the frontal cortex. LBs were observed mostly in grey matter
in some of the PD cases, and in most of the PDD and DLB
cases (Figures 4(a)–4(c)). We also saw LNs (Figures 4(a)–
4(d), arrowheads), the presence of which correlated with
the number of LBs. Occasionally, we observed some LBs
in the white matter (Figure 4(d)), in PD, PDD, and DLBParkinson’s Disease 7
Table 3: Median results per group.
Diagnosis GFAP GM
(surface %)
GFAP WM
(surface %)
Vimentin GM
(cells per mm3)
Vimentin WM
(cells per mm3) GFAP CSF Vimentin CSF Lewy bodies
(per mm3)
Control 1.22 1.37 963.3 3123 2.76 0 0.0
PD 0.99 0.92 761.2 1336 11.62 1.17 1.1
PDD 1.13 1.27 705.6 2533 1.98 0 29.8
DLB 1.12 1.00 1084.0 1965 4.36 0 19.2
Control: nondemented control; PD: Parkinson’s disease; PDD: PD with dementia; DLB: dementia with Lewy bodies; GM: grey matter; WM: white matter;
CSF: cerebrospinal ﬂuid.
C
(a)
PD
(b)
PDD
(c)
DLB
GM
(d)
(e) (f) (g)
WM
(h)
0
1
2
3
4
C PD PDD DLB
GFAP-positive area (%) GM
∗
(i)
0
1
2
3
4
C PD PDD DLB
GFAP-positive area (%) WM
∗
(j)
Age
75
0
1
2
3
4
60 65 70 80 85 90
GFAP-expression (%) GM
(k)
Figure 1: GFAP immunoreactivity in the human frontal cortex. (a–h) examples of GFAP immunoreactivity in grey (a–d) and white matter
(e–h) of a 77-year-old female control (C) donor (NBB 2001-104; a, e), a 77-year-old male Parkinson’s disease (PD) patient (NBB 2005-069;
b, f), a 71-year-old male Parkinson’s disease with dementia (PDD) patient (NBB 2004-045; c, g), and 76-year-old female dementia with Lewy
bodies (DLB) patient (2001-025; d, h). (i-j) Boxplot of the quantiﬁcation of GFAP staining in grey (i) and white matter (j) of 8 C, 6 PD,
11 PDD, and 9 DLB cases. (k) correlation of GFAP expression in the grey matter with age of the 34 donors. GM: grey matter; WM: white
matter; inserts show higher magniﬁcation images of the same patients. Scale bars represent 50μm for the lower magniﬁcation and 20μmf o r
the higher magniﬁcation images.
cases. It has to be established whether these white matter
LBs are present in axons or glia cells. Astrocytes have been
described to contain α-synuclein [21]a n dL B si nP D[ 34].
When quantifying the LB numbers (Figure 4(e), Table 3), we
observed a signiﬁcant diﬀerence between all groups (P<
0.001). When we compared the groups one by one, we found
a signiﬁcant diﬀerence between the control and PD groups
(P = 0.043) and between the PD and PDD groups (P =
0.002). PD Braak stages were known for half of the cases in
our group, and LB pathology correlated highly with these
(r = 0.727, P<0.0001), as expected. In addition, LB
pathology was signiﬁcantly diﬀerent depending on the ApoE
genotype (Figure 4(f), P = 0.041). When we analyzed the
alleles separately, we found a highly signiﬁcant diﬀerence in8 Parkinson’s Disease
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Figure 2: Vimentin immunoreactivity in the human frontal cortex. (a–h) examples of vimentin immunoreactivity in grey (a–d) and white
matter (e–h) of a 71-year-old male control (C) donor (NBB 2002-087; a, e), a 86-year-old male Parkinson’s disease (PD) patient (NBB 2001-
122; b, f), a 75-year-old female Parkinson’s disease with dementia (PDD) patient (NBB 2003-059; c, g), and 72-year-old male dementia with
Lewy bodies (DLB) patient (2002-017; d, h). (i-j) Boxplot of the quantiﬁcation of vimentin staining in grey (i) and white matter (j) of 8 C,
6 PD, 11 PDD, and 9 DLB cases. Outliers are shown as dots. (k) correlation of vimentin expression in the grey matter with age of the 34
donors. GM: grey matter; WM: white matter; inserts show higher magniﬁcation images of the same patients. Scale bars represent 50μmf o r
the lower magniﬁcation and 20μm for the higher magniﬁcation images.
LB number between donors carrying an ε4 allele and donors
not carrying this allele (P = 0.002). Surprisingly, the LB
counts also correlated negatively with GFAP levels in CSF
(r =− 0.385;P = 0.033).Wedidnotﬁndfurthercorrelations
between LBs and clinicopathological data, such as sex (P =
0.322), PMD (P = 0.065), and amyloid score (P = 0.659).
4. Discussion
We have shown that astrogliosis in the frontal cortex of
PDD and DLB patients is not increased compared to PD
patients. In addition, we showed that there is no correlation
between GFAP and vimentin levels in CSF and the cognitive
status in these three LB disorders. Therefore, astrogliosis, as
demonstrated by GFAP levels and the number of vimentin-
positive astrocytes, does not seem to contribute to the
frontal-type dementia in PDD and DLB. Furthermore, we
showed that cortical LB pathology is not associated with
an increase in cortical astrogliosis in PD, PDD, and LBD
patients. However, we could conﬁrm the earlier reported
correlation of an increase in GFAP and vimentin in grey
matterwith increasing ageand the association of α-synuclein
pathology in the frontal cortex with LB-related dementia.
The increase in GFAP and vimentin in the aging brain
is in agreement with previous studies showing a gradual
increase of GFAP in astrocytes throughout the adult lifespan
of mice, rats, and humans [35, 36]. While astrocyte cell
size and processes increase with age, the total number of
astrocytes seems to be unchanged [37]. The cause of the
increaseinreactiveastrogliosisintheagedbrainisunknown,
b u ti th a sb e e np r o p o s e dt h a ti tm a yb ear e s p o n s et o
oxidative stress and inﬂammation in the aging brain [38].
In contrast to previous studies in rodents [39, 40], no
correlation between astrogliosis in cortical white matter
and age was found. This discrepancy might be caused by
species diﬀerences between human astrocytes and rodent
astrocytes [41]. The diﬀerence between grey and white
matter astrocytes may relate to the presence of neuronal cell
bodies in grey matter. If astrogliosis is indeed a response
to neuronal damage [42], it seems logical that grey matterParkinson’s Disease 9
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Figure 3: Astrocytic protein levels in ventricular cerebrospinal ﬂuid (CSF). (a) example of a Western blot for GFAP (top row) and vimentin
(bottom row) on CSF of diﬀerent donors (from left to right: NBB 2006-030, 2007-007, 2007-008, 2007-019, 2005-017, 2005-050, 2005-055,
2005-069, and 2005-077). (b) correlation of the GFAP and vimentin protein levels (in arbitrary units) in CSF of 36 donors. (c) Boxplot of
GFAP protein levels in CSF of 8 control (c), 8 Parkinson’s disease (PD), 11 PD with dementia (PDD), and 9 dementia with Lewy bodies
(DLB) cases. (d) Boxplot of vimentin protein levels in CSF of 8 C, 8 PD, 11 PDD, and 9 DLB cases.
astrocytes will respond more to aging. Vimentin is not
exclusively expressed by astrocytes in the brain. In our study,
we also observed a strong vimentin signal in the capillaries;
therefore,wecouldnotperformanautomatedimageanalysis
method to measure the vimentin intensity. Next to this, also
microglia express vimentin [43], and microglia have been
observed to respond to α-synuclein accumulations in the
substantia nigra of PD patients [44]. Since the vimentin
expression pattern followed that of GFAP and since the
morphology of the GFAP-positive cells was highly similar to
the vimentin positive cells and reminiscent of astrocytes, we
do not expect that potentially vimentin positive microglia
aﬀect our data. Our study showed that GFAP and vimentin
levelsinpostmortemCSFcorrelatedwell,whichsuggeststhat
levels of these proteins in CSF accurately reﬂect astrogliosis.
We could detect vimentin in CSF only in a subset of
donors, suggesting that vimentin protein is less stable than
GFAP. There was no distinct group of donors that expressed
vimentin in CSF, which indicates that the stability is not
dependent on disease. Furthermore, there was no correlation
with postmortem delay or pH of the CSF. Surprisingly, we
did not ﬁnd a correlation between astrocytic protein levels in
CSFandastrogliosisinthefrontalcortex.Thismightindicate
that ventricular CSF levels of astrocytic proteins reﬂect
astrogliosis in other areas, probably closer to the ventricle.
There is evidence that protein levels vary in CSF samples
from diﬀerent areas, that is, ventricular versus lumbar CSF
[45] and lumbar versus cisternal CSF [46]. It seems logical
thenthatCSFfromdiﬀerentcompartmentsdiﬀerentlyreﬂect
tissue levels of these proteins.
ThelevelsofGFAPandvimentininCSFdidnotcorrelate
with the severity of the cognitive impairment in PDD or
DLB. There were also no diﬀerences in CSF-GFAP levels
between the four diagnostic groups, showing that GFAP
in CSF cannot be used as an indicator for astrogliosis or
dementia in PD. These ﬁndings are in agreement with10 Parkinson’s Disease
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Figure 4: α-synuclein pathology in the human frontal cortex. (a–c) Lewy bodies (arrows) and Lewy neurites (arrowheads) in the grey matter
of a Parkinson’s disease (PD; NBB 1999-038), Parkinson’s disease with dementia (PDD; NBB 2004-045), and dementia with Lewy bodies
(DLB; NBB 1997-092) case. (d) a Lewy body (arrow) in the white matter (WM) of the frontal cortex of case NBB 2004-045. (e) Boxplot of
the quantiﬁcation of Lewy body number in the frontal cortex of 8 control, 6 PD, 11 PDD, and 9 DLB cases. (f) Lewy body numbers per ApoE
genotype. Scale bars represent 100μm.
previous studies on PD CSF from lumbar punctures [47, 48].
We now describe that vimentin levels in CSF show the
same lack of correlations, making it equally unsuitable as
a biomarker for PD or dementia in PD. Levels of GFAP in
CSF of AD cases are elevated and correlate to the severity
of dementia [15], which is in contrast with our ﬁndings in
PD cases. Therefore, we suggest that the pathological process
underlying dementia in these two neurological disorders
is diﬀerent. This might be related to the nature of the
aggregates in both diseases; LBs are found intracellularly,
whereas Aβ accumulates extracellularly, thereby triggering
astrogliosis. We did ﬁnd that GFAP was expressed highly
in CSF in a PD donor that died after a stroke, which is in
accordance with an earlier report [49]. Vimentin expression
was not remarkably high in this patient, which is surprising,
since vimentin is upregulated in tissue from stroke patients
[50].
Our ﬁnding that LB pathology correlates with cognitive
parameters in LB-related dementias is in agreement with two
previous studies. One of these studies identiﬁed LB load in
the frontal cortex as the most signiﬁcant indicator of cog-
nitive impairment in PD patients, as measured by the GDS
scale [27]. A later study reported on a correlation between
frontal LBs and cognition and identiﬁed the entorhinal and
anterior cingulate cortex as better predictors [51]. For DLB,
no correlation was found between cortical LB pathology
and dementia severity [52]. We ﬁnd a similar number of
frontalLBsinPDDandDLB,whichisinaccordancewiththe
current thought that cortical LB pathology cannot be used to
diﬀerentiate between DLB, PD, or PDD [53].
Aggregates of α-synuclein have not only been observed
in Lewy neurites and in neuronal Lewy bodies but also in the
cytoplasm of astrocytes [21, 34]. These ﬁndings contributed
to the novel idea that glia dysfunction is involved in the
pathogenesis of PD and other α-synucleinopathies. The
accumulation of α-synuclein in astrocytes is proposed to be
involved in initiating a long-lasting microglia response and
reactive gliosis leading to neuronal degeneration [54, 55].
In our study, we did not discriminate between glial and
neuronal α-synuclein inclusions. Unexpectedly, however,
we observed that the number of LBs negatively correlated
with GFAP levels in CSF. This ﬁnding underscores that α-
synuclein does not lead to astrogliosis, and that α-synuclein
might even reduce the reactivity of astrocytes [21], which
might explain the decrease in GFAP levels in the CSF in
patients with a higher number of LBs.
The association we have found between the ApoE gen-
otype and α-synuclein-positive LBs has been suggested
before. Parkinson patients have been reported to have an
overrepresentation of the ε2[ 56]o ro ft h eε4[ 57] allele. An
extensive meta-analysis identiﬁed a correlation between the
ApoE ε4 allele and dementia in PD [56], but other studies
have disputed this association [57, 58]. These mixed results
may be a consequence of the variable amount of Alzheimer’sParkinson’s Disease 11
pathology present in the diﬀerent patient groups. We did
not ﬁnd an association between ApoE genotype and clinical
phenotype, but we did observe more cortical α-synuclein
pathology in carriers of the ε4 allele, which is in agreement
with a previous study [27]. What these ﬁndings mean for the
aetiology and disease progression of PD and PDD remains
to be elucidated. One study has shown, using transgenic
mice overexpressing mutant α-synuclein, that α-synuclein-
inducedneurodegenerationinvolvesApoEupregulation,and
that ApoE further contributes to the disease process. In
addition, amyloid beta was accumulating in this model, and
the ubiquitin-proteasome system was disturbed, suggesting
a common pathway between PD and AD [59]. The involve-
ment of ApoE in PD and/or PDD is an indication that
astrocytesareinvolved in the disease, since ApoE is expressed
primarily by astrocytes [60]. Again, how this relates to the
aetiology of PD and PDD needs further examination.
We did not ﬁnd a diﬀerence in astrogliosis or LB
pathology in the frontal cortex between PDD and DLB.
Currently, these two disorders are considered to be two
clinical phenotypes of the same disease spectrum, and no
markers have been found to distinguish the two conditions
(reviewedin[61]).Itisalsonotpossibletomakeadistinction
between the two phenotypes based on neuropsychological
tests (reviewed in [62]). We found that the GDS score was
on average higher in DLB cases than in PDD cases, but our
results may be biased because we investigated the end stage
of the disease. A factor that may distinguish between PDD
and DLB is β-amyloid (Aβ). Striatal Aβ pathology is higher
in DLB than in PDD [63, 64]. In addition, cortical Aβ load
is signiﬁcantly higher in DLB than in PDD, which could be
measured in a PET scanner [65]. In our study, we did not
ﬁnd a correlation between amyloid scores and dementia or
increased amyloid scoresin DLB versusPDD,butweselected
the cases for early Alzheimer stages, which might skew our
data.
In summary, in the present study we could conﬁrm
that LB pathology in the frontal cortex was associated with
dementia in LB-related dementias. However, we could not
ﬁnd any indication for an increase in astrogliosis in cortical
areas in PDD and DLB brains or for a correlation between
theextentofcorticalastrogliosisanddementia.Furthermore,
we showed that the presence of GFAP or vimentin in CSF
could not be used as an indicator of astrogliosis or dementia.
In conclusion, reactive gliosis is not associated with the
cognitive impairment in LB-related dementias, in contrast to
what has been reported for AD.
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